- Condition: Healthy Volunteer
Interventions: Drug: RO4917523; Drug: RO4917523
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified May 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO5093151; Drug: ketoconazole; Drug: rifampicin; Drug: atazanavir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified May 2012 - Condition: Neoplasms
Intervention: Drug: bevacizumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: boceprevir; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin (Copegus]; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin (Copegus]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Gastric Cancer
Interventions: Drug: Onartuzumab; Drug: Placebo; Drug: mFOLFOX6
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Chronic Hepatitis C
Interventions: Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 1; Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3
Sponsors: Asan Medical Center; Asan Medical Center; Samsung Medical Center; Severance Hospital; Gangnam Severance Hospital; Seoul St. Mary's Hospital; Korea University Guro Hospital
Completed - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: XELOX; Drug: bevacizumab [Avastin]; Drug: mFOLFOX6; Drug: bevacizumab [Avastin]; Drug: FOLFIRI
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Other: Blood analysis by EPISPOT and Cellsearch
Sponsors: University Hospital, Montpellier; University Hospital, Montpellier; National Cancer Institute, France; Direction Générale de l'Offre de Soins; Roche Pharma AG
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: ribavirin [Copegus]; Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: tenofovir disoproxil fumarate; Drug: atazanavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: danoprevir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: efavirenz
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO5508887; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Clalit Health Services
Not yet recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]; Drug: danoprevir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Breast Cancer Invasive Nos
Intervention:
Sponsors: Spanish Breast Cancer Research Group; Spanish Breast Cancer Research Group; Hoffmann-La Roche; Roche Farma, S.A.
Not yet recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: RoActemra/Actemra (tocilizumab)
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel; Drug: Paclitaxel
Sponsors: German Breast Group; German Breast Group; Celgene GmbH; Roche Pharma AG
Not yet recruiting - verified April 2012 - Conditions: Breast Cancer; Lymphedema
Intervention:
Sponsors: Stanford University; Stanley Rockson
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: taxane
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Pneumonia Due to Staphylococcus Aureus
Interventions: Drug: KBSA301; Drug: Placebo
Sponsors: Kenta Biotech Ltd; Kenta Biotech Ltd
Recruiting - verified May 2012 - Condition: Early Mobilisation in Ischemic Stroke Patients
Intervention: Other: Mobilization of stroke patients
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: BKM120; Drug: Paclitaxel; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: vinorelbine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Lung Cancer
Interventions: Drug: Erlotinib; Drug: Bevacizumab
Sponsors: European Thoracic Oncology Platform; European Thoracic Oncology Platform; Spanish Lung Cancer Group
Not yet recruiting - verified April 2012 - Condition: Down Syndrome
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified March 2012 - Condition: Colorectal Cancer.
Intervention: Radiation: Stereotactic body radiotherapy
Sponsors: Sunnybrook Health Sciences Centre; Dr. Yoo-Joung Ko; Roche Pharma AG
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: Tamiflu (oseltamivir); Drug: Tamiflu (oseltamivir)
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: HER-2 Positive Breast Cancer
Interventions: Drug: T-DM1; Procedure: 89Zr-trastuzumab
Sponsors: Jules Bordet Institute; Jules Bordet Institute; Roche Pharma AG
Not yet recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate; Drug: methotrexate; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Subjects
Interventions: Drug: Filgrastim; Drug: Filgrastim; Drug: Filgrastim; Drug: Filgrastim
Sponsors: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.; L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
Not yet recruiting - verified March 2012 - Condition: Gastric Adenocarcinoma
Intervention: Drug: Capecitabine, Oxaliplatin, Docetaxel
Sponsors: National Health Research Institutes, Taiwan; National Health Research Institutes, Taiwan; Taipei Veterans General Hospital,Taiwan; Tri-Service General Hospital; Mackay Memorial Hospital; National Cheng-Kung University Hospital
Active, not recruiting - verified March 2012 - Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: Rituximab, CMC544, Gemcitabine and Oxaliplatine
Sponsors: Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique; Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique; Pfizer
Not yet recruiting - verified March 2012 - Condition: Metastatic Breast Cancer Starting a Third Line Chemotherapy
Intervention: Other: Construction of a prognostic score (non-drug intervention types)
Sponsors: Institut Claudius Regaud; Institut Claudius Regaud
Not yet recruiting - verified May 2012 - Conditions: Anxiety; Depression; Posttraumatic Stress Disorder
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO4917838; Drug: Placebo to RO4917838; Other: Alcohol
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified February 2012 - Conditions: Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Circulating Tumor Cells
Intervention: Drug: trastuzumab
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; Hoffmann-La Roche
Not yet recruiting - verified March 2012 - Conditions: Colorectal Cancer; Intravenous 5 Fluorouracile
Interventions: Genetic: Blood sample for phenotypic and pharmacogenetic analysis.; Genetic: Blood sample for phenotypic and pharmacogenetic analysis.
Sponsors: ICO Paul Papin; ICO Paul Papin
Recruiting - verified March 2012 - Conditions: Metastatic Breast Cancer; Progesterone Receptor Positive Tumor; Estrogen Receptor Positive Tumor; HER-2 Negative Tumor
Interventions: Dietary Supplement: Dietary supplementation with fish oil.; Dietary Supplement: Dietary supplementation with vegetable oil
Sponsors: University Hospital, Tours; University Hospital, Tours; ICO Paul Papin
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Sclerosis, Systemic
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Rhabdomyolysis; Acute Kidney Failure
Intervention: Biological: Plasma NGAL level
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified February 2012 - Condition: Arthroplasty, Replacement, Hip
Interventions: Drug: Standard Care morphine hydrochloride; Drug: Oxycodone
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified February 2012 - Condition: Multiple Myeloma, Neoplasms
Intervention: Drug: Vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: darunavir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Sponsors: Johannes Gutenberg University Mainz; Johannes Gutenberg University Mainz; Roche Pharma AG
Not yet recruiting - verified April 2012 - Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified January 2012 - Condition: Healthy
Interventions: Drug: Mycophenolate Mofetil; Drug: Mycophenolate Mofetil
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Condition: Healthy
Interventions: Drug: Mycophenolate Mofetil; Drug: Mycophenolate Mofetil
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: raltegravir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: Anemia, Kidney Disease, Chronic
Intervention: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: trastuzumab emtansine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: cyclosporine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: T-cell Lymphoma
Intervention: Drug: Lenalidomide
Sponsors: Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique; Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified January 2012 - Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Drug: dalcetrapib; Drug: Placebo; Other: Background care
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO4917838; Drug: RO4917838
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: RO6807952; Drug: RO6807952; Drug: Placebo; Drug: liraglutide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Terminated - verified February 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified February 2012 - Condition: Liver Cancer
Interventions: Drug: RO5137382; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Hepatitis B, Chronic
Intervention: Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified January 2012 - Conditions: Colorectal Cancer Metastatic; Liver Metastases; KRAS Wild Type Colorectal Cancer
Intervention: Drug: 5-FU, Folinic Acid, Oxaliplatin, Bevacizumab, Panitumumab
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; Amgen; Roche Pharma AG
Not yet recruiting - verified January 2012 - Condition: DMARD Resistant Rheumatoid Arthritis
Interventions: Drug: Rituximab; Drug: Rituximab
Sponsors: Mashhad University of Medical Sciences; Mashhad University of Medical Sciences; Roche Pharma AG
Completed - verified May 2012 - Conditions: Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Recurrent
Intervention:
Sponsors: Chonnam National University Hospital; Chonnam National University Hospital; Roche Pharma AG
Recruiting - verified January 2012 - Condition: Non-Small Cell Lung Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Hepatitis B; Renal Failure With Tubular Necrosis
Intervention: Biological: plasma and urine samples, sample with ADN
Sponsors: University Hospital, Limoges; University Hospital, Limoges
Recruiting - verified December 2011 - Condition: End Stage Renal Disease
Intervention: Drug: High dose IVIG and B cell depleting agents
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Roche Pharma AG
Enrolling by invitation - verified January 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO4917838; Drug: valproate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified February 2012 - Condition: Breast Cancer, Colorectal Cancer
Interventions: Drug: capecitabine RTD; Drug: capecitabine [Xeloda]; Drug: capecitabine [Xeloda]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Hypertension, Ocular, Glaucoma, Open-Angle
Interventions: Drug: RO5093151; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: paclitaxel; Drug: cisplatin/carboplatin
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - Insulin glargine; Drug: HOE901 - Insulin glargine-new formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Non-ST Elevation Myocardial Infarction
Interventions: Drug: Tocilizumab 280 mg; Drug: NaCl 0.9% 100 ml
Sponsors: Oslo University Hospital; Oslo University Hospital; St. Olavs Hospital; South-Eastern Norway Regional Health Authority; University of Oslo; Norwegian University of Science and Technology
Recruiting - verified December 2011 - Condition: Non-Small Cell Lung Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified December 2011 - Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Tamoxifen,; Drug: Exemestane; Drug: Anastrozole; Drug: Letrozole
Sponsors: Institut Claudius Regaud; Institut Claudius Regaud
Recruiting - verified March 2012 - Condition: Glioblastoma
Interventions: Radiation: Radiotherapy; Radiation: Experimental arm
Sponsors: Institut Claudius Regaud; Institut Claudius Regaud
Recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Neoplasms
Interventions: Drug: RO5509554; Drug: paclitaxel; Drug: RO5509554
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: danoprevir; Drug: danoprevir; Drug: ritonavir; Drug: ritonavir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified December 2011 - Condition: Non Hodgkin Lymphoma
Intervention: Drug: Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)
Sponsors: National University Hospital, Singapore; National University Hospital, Singapore
Not yet recruiting - verified March 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO4917523; Drug: RO5011232
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: mericitabine; Drug: mericitabine; Drug: Placebo; Drug: Placebo; Drug: Pegasys; Drug: Copegus; Drug: Pegasys; Drug: Copegus; Drug: telaprevir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Neoplasms
Interventions: Drug: RO5479599; Drug: cetuximab; Drug: erlotinib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: mericitabine; Drug: Placebo; Drug: boceprevir; Drug: boceprevir; Drug: boceprevir; Drug: Placebo; Drug: Pegasys; Drug: Copegus; Drug: Pegasys; Drug: Copegus
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C
Intervention: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Discal Sciatica
Interventions: Drug: Prednisolone acetate; Drug: sham procedure; Drug: comparator : physiological solution
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified September 2011 - Condition: Autistic Disorder
Interventions: Drug: RO5028442; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 1
Intervention: Device: Accu-Chek DiaPort
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified November 2011 - Condition: Healthy Volunteer
Intervention: Drug: dalcetrapib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: Femur Neck Fracture
Interventions: Drug: Teriparatide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Glioblastoma Multiforme
Interventions: Drug: bevacizumab; Drug: fotemustine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab; Drug: tocilizumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Lymphocytic Leukemia, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Chronic Hepatitis B
Intervention: Drug: Pegylated interferon alfa-2a
Sponsors: Beijing Ditan Hospital; Beijing Ditan Hospital
Recruiting - verified November 2011 - Condition: Chronic Hepatitis C
Intervention: Drug: Pegylated interferon alfa-2a and ribavirin
Sponsors: Beijing Ditan Hospital; Beijing Ditan Hospital
Completed - verified October 2011 - Condition: Neoplasms
Interventions: Drug: RO5503781; Drug: RO5503781
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage IIIA; Epithelial Growth Factor Receptor Positive Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea; Hoffmann-La Roche
Recruiting - verified November 2011 - Condition: Gastric Cancer
Interventions: Drug: pertuzumab; Drug: pertuzumab; Drug: trastuzumab; Drug: cisplatin; Drug: capecitabine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Athletes; Training; Fatigue
Intervention: Device: ANS activity
Sponsors: Centre Hospitalier Universitaire de Saint Etienne; Centre Hospitalier Universitaire de Saint Etienne; Minister of Youth Affairs and Sports, France
Enrolling by invitation - verified October 2011 - Condition: Healthy Volunteer
Interventions: Drug: RO5508887; Drug: Placebo; Drug: RO5508887
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified October 2011 - Condition: Osteoarthritis, Knee
Intervention:
Sponsors: Orthosensor, Inc.; Orthosensor, Inc.
Recruiting - verified January 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Depression Disorder, Major
Interventions: Drug: RO4995819; Drug: RO4995819; Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Glaucoma
Interventions: Drug: Gingko Biloba; Drug: α−tocopherol; Drug: Placebo; Drug: Antioxidant formula
Sponsors: Bagcilar Training and Research Hospital; Bagcilar Training and Research Hospital
Completed - verified February 2012 - Condition: Rheumatoid Arthritis, Arthritis, Juvenile Rheumatoid
Intervention: Drug: Tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach
Interventions: Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab; Drug: Post-operative treatment trastuzumab mono therapy
Sponsors: AIO-Studien-gGmbH; AIO-Studien-gGmbH; Roche Pharma AG
Recruiting - verified January 2012 - Condition: Mantle Cell Lymphoma
Intervention: Drug: RiBVD
Sponsors: Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS; Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS; Lymphoma Study Association; Janssen-Cilag Ltd.; Mundipharma; Roche Pharma AG; Chugai Pharma Europe Ltd.
Recruiting - verified October 2011 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Influenza
Intervention: Drug: Oseltamivir
Sponsors: Trial Management Group Inc.; Trial Management Group Inc.; Hoffmann-La Roche
Active, not recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012 - Condition: Hepatitis B, Chronic
Interventions: Drug: Peginterferon alfa-2a; Drug: Entecavir
Sponsors: Gangnam Severance Hospital; Gangnam Severance Hospital; Roche Pharma AG
Not yet recruiting - verified October 2011 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a; Drug: ribavirin [Copegus]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Ischemia
Intervention: Drug: beta-epoietin
Sponsors: University Hospital, Limoges; University Hospital, Limoges; Hoffmann-La Roche
Recruiting - verified December 2011 - Condition: Hepatitis C
Interventions: Drug: BMS-790052 (NS5A Replication Complex Inhibitor); Drug: Placebo matching BMS-790052; Drug: Pegylated-interferon alfa 2a; Drug: Pegylated-interferon alfa 2a; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Giant Cell Arteritis
Interventions: Drug: Tocilizumab + Glucocorticoids (GCs); Drug: Placebo + Glucocorticoids (GCs)
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; CTU Bern; Roche Pharma AG
Recruiting - verified October 2011 - Condition: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Device: ACCU-CHEK AVIVA EXPERT MMOL/L (651); Other: No Intervention
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified August 2011 - Condition: Metastases
Interventions: Drug: Leuprorelin Acetate ((Eligard® ); Other: Reference arm
Sponsors: UNICANCER; UNICANCER
Active, not recruiting - verified September 2011 - Condition: Healthy Volunteer
Interventions: Drug: RO4917838; Drug: diazepam; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Depression Disorder, Major
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Renal Cell Carcinoma
Interventions: Drug: everolimus; Drug: GDC-0980
Sponsors: Genentech; Genentech
Not yet recruiting - verified September 2011 - Condition: Diabetes Mellitus
Interventions: Device: Self monitoring blood glucose system; Device: Self monitoring blood glucose system
Sponsors: Abbott Diabetes Care; Abbott Diabetes Care
Active, not recruiting - verified March 2012 - Condition: Chronic Hepatitis C
Intervention: Dietary Supplement: Vit D
Sponsors: Hanyang University; Hanyang University; Roche Pharma AG
Not yet recruiting - verified September 2011 - Condition: Central Nervous System Lymphoma
Intervention: Drug: Immunochemotherapy
Sponsors: University of Aarhus; University of Aarhus; Nordic Cancer Union; Roche Pharma AG; Mundipharma; Schering-Plough
Active, not recruiting - verified October 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rectal Cancer
Intervention: Drug: capecitabine, oxaliplatin, bevacizumab
Sponsors: Austrian Breast & Colorectal Cancer Study Group; Austrian Breast & Colorectal Cancer Study Group; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: HER-2 Positive Breast Cancer
Intervention:
Sponsors: Asociación para el Progreso de la Oncología en Málaga; Asociación para el Progreso de la Oncología en Málaga; Roche Farma, S.A.
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO4917838; Drug: RO4917838
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified October 2011 - Condition: Colorectal Cancer
Interventions: Drug: Oxaliplatin; Drug: Folinic Acid; Drug: 5-fluoro-uracil; Drug: Irinotecan; Drug: Bevacizumab; Drug: Cetuximab
Sponsors: UNICANCER; UNICANCER
Recruiting - verified September 2011 - Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052 (HCV NS5A Replication Co-factor Inhibitor); Drug: BMS-650032 (HCV NS3 Protease Inhibitor); Drug: Peginterferon alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Anemia, Kidney Disease, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Trastuzumab; Drug: Paclitaxel; Drug: Epirubicin; Drug: Carboplatin
Sponsors: Fudan University; Zhimin Shao; Roche Pharma AG
Recruiting - verified September 2011 - Condition: Down Syndrome
Interventions: Drug: RG1662; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: paclitaxel plus trastuzumab
Sponsors: WiSP Wissenschaftlicher Service Pharma GmbH; WiSP Wissenschaftlicher Service Pharma GmbH; Bristol-Myers Squibb GmbH; Roche Pharma AG
Completed - verified August 2011 - Condition: Healthy Volunteer
Interventions: Drug: tocilizumab [RoActemra/Actemra] auto-injector; Drug: tocilizumab [RoActemra/Actemra] Syringe
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO5285119; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer
Interventions: Drug: Carboplatin; Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
Sponsors: German Breast Group; German Breast Group; Cephalon; Roche Pharma AG; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Anemia
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO4995819; Drug: activated charcoal
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: Oxaliplatin; Drug: Folinic Acid; Drug: 5-fluoro-uracil; Drug: Irinotecan; Drug: Irinotecan; Drug: Bevacizumab; Drug: Cetuximab
Sponsors: UNICANCER; UNICANCER
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate; Drug: methotrexate; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: escitalopram
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: Colorectal Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: lisinopril; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: danoprevir; Drug: ritonavir; Drug: moxifloxacin; Drug: danoprevir placebo; Drug: ritonavir placebo; Drug: moxifloxacin placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Conditions: Early Onset Alzheimer Disease; Alzheimer Disease; Obstructive Sleep Apnea Syndromes
Interventions: Device: CPAP Treatment; Device: No treatment
Sponsors: Centre Hospitalier Universitaire de Saint Etienne; Centre Hospitalier Universitaire de Saint Etienne; Association Lyonnaise de Logistique Posthospitalière
Recruiting - verified February 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO5267683; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Lymphocytic Leukemia, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified July 2011 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: MEGF0444A; Drug: mFOLFOX6; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Melanoma
Interventions: Drug: Ipilimumab (BMS-734016); Biological: Vemurafenib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Roche-Genentech
Recruiting - verified November 2011 - Condition: Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: ARCAGY/ GINECO GROUP; ARCAGY/ GINECO GROUP
Recruiting - verified February 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Renal Cell Cancer
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: omeprazole; Drug: ranitidine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A; Drug: MABT5102A; Drug: placebo; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified August 2011 - Conditions: Metastatic or Recurrent Gastric Adenocarcinoma; Her-2 Positive Gastric Cancer
Intervention: Drug: Herceptin+XELOX
Sponsors: Asan Medical Center; Asan Medical Center; Hoffmann-La Roche
Recruiting - verified December 2011 - Condition: Advanced Gastric Cancer
Intervention: Drug: Docetaxel, Capecitabine, Cisplatin, Bevacizumab
Sponsors: Asan Medical Center; Asan Medical Center; Roche Pharma AG
Recruiting - verified November 2011 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified July 2011 - Condition: Glioma
Interventions: Drug: temozolomide (TMZ); Drug: bevacizumab [Avastin]; Radiation: Radiotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: methadone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's LymphomaCondition: Non-Hodgkin's Lymphoma
Intervention: Drug: rituximab [MabThera/Rituxan]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified July 2011 - Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: rituximab [MabThera/Rituxan]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified July 2011 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Neoplasms
Intervention: Drug: RO5458640
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: mFOLFOX6
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Ulcerative Colitis
Intervention:
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals; ANGH: Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux de France; CREGG: Club de Réflexion des Cabinets et Groupes d'Hépato-Gastroentérologie
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: methotrexate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Anemia, Kidney Disease, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Physical Activity
Interventions: Behavioral: Counseling; Behavioral: physical activity
Sponsors: Arbeitsgemeinschaft medikamentoese Tumortherapie; Arbeitsgemeinschaft medikamentoese Tumortherapie; Roche Pharma AG
Recruiting - verified June 2011 - Conditions: Sustained Virologic Response; IL28B Polymorphism
Interventions: Drug: peginterferon alfa 2a (pegasys); Drug: peginterferon alfa-2a (pegasys)
Sponsors: The Catholic University of Korea; The Catholic University of Korea; Ulsan University Hospital; NHIC Ilsan hospital; Inje University; Soonchunhyang University Hospital; Yonsei University; Chungnam National University; Keimyung University; Kyungpook National University; Konyang University Hospital; Inha University Hospital; Hallym University Medical Center
Recruiting - verified October 2008 - Condition: Cytomegalovirus Infections, Kidney Transplantation
Intervention: Drug: valganciclovir [Valcyte]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid ArthritisCondition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified October 2011 - Condition: Hepatitis C, Chronic, Healthy Volunteer
Interventions: Drug: RO5428029; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Acute Coronary Syndrome
Interventions: Device: Cardiac Biomarker testing.; Device: Point of Care testing
Sponsors: Integrated Medical Research LLC; Integrated Medical Research LLC; Alere San Diego; New York State Department of Health
Completed - verified March 2012 - Condition: Solid Cancers
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011 - Condition: Chronic Hepatitis B
Interventions: Drug: Peginterferon alfa-2a; Drug: Nucleos(t)ide analogue
Sponsors: Foundation for Liver Research; Foundation for Liver Research; Hoffmann-La Roche
Not yet recruiting - verified February 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885 tablet; Drug: GS-9451 tablet; Biological: peginterferon alfa-2a; Drug: ribavirin tablet
Sponsors: Gilead Sciences; Gilead Sciences
Active, not recruiting - verified December 2011 - Condition: Breast Cancer
Intervention: Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: dalcetrapib; Drug: atorvastatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified January 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Spanish Breast Cancer Research Group; Spanish Breast Cancer Research Group; Roche Farma, S.A.
Completed - verified June 2011 - Condition: Basal Cell Carcinoma
Intervention: Drug: vismodegib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO4995819; Drug: placebo; Drug: citalopram
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified February 2012 - Condition: NSCLC
Interventions: Drug: Bevacizumab; Drug: Cisplatin; Drug: Docetaxel
Sponsors: Arbeitsgemeinschaft medikamentoese Tumortherapie; Arbeitsgemeinschaft medikamentoese Tumortherapie; Sanofi-Aventis; Roche Pharma AG
Recruiting - verified June 2011 - Condition: Healthy Volunteer
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified February 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: placebo; Drug: carboplatin; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: MEGF0444A; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel; Drug: Trastuzumab, Docetaxel, Bevacizumab; Drug: Trastuzumab+Docetaxel+NPLD; Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
Sponsors: Austrian Breast & Colorectal Cancer Study Group; Austrian Breast & Colorectal Cancer Study Group; Hoffmann-La Roche; Cephalon
Recruiting - verified April 2012 - Conditions: Cytomegalovirus Infection; Hepatitis C
Intervention:
Sponsors: Sociedad Española de Trasplante Hepático; Sociedad Española de Trasplante Hepático; Roche Farma, S.A.
Recruiting - verified November 2011 - Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid TumorsCondition: Solid Tumour
Intervention: Drug: MFGR1877S
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Non-Small Cell Lung Cancer, Ovarian Cancer
Intervention: Drug: DNIB0600A
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Solid Cancers
Interventions: Drug: docetaxel; Drug: GDC-0068; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
 |
Hoffmann - La Roche - Database of Clinical Trials by Pharmaceutical Companies |
